A recent retrospective analysis from a group of n = 71 adults with isocitrate dehydrogenase 1 (IDH1) wild-type GBM treated with standard therapy plus IMI revealed a 2-year overall survival (2y OS) of 42.7% for MGMT-promoter unmethylated types and 75.5% for MGMT-promoter methylated types [50]. Here, MGMT is linked to glioblastoma.